Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isaure Vanmeerbeek

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Molecular Oncology|January 21, 2026
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunityIsaure Vanmeerbeek, Jenny Sprooten, Abhishek D Garg
Genes and Immunity|June 3, 2021
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapyIsaure Vanmeerbeek, Daniel M Borras, Jenny Sprooten, et al.
Immunological Reviews|November 8, 2023
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapyRaquel S Laureano, Isaure Vanmeerbeek, Jenny Sprooten, et al.
Cells|December 11, 2022
The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-OncologyIsaure Vanmeerbeek, Jannes Govaerts, Raquel S Laureano, et al.
Oncoimmunology|February 1, 2020
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncologyIsaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
Oncoimmunology|October 14, 2024
Trial watch: anticancer vaccination with dendritic cellsFrancisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, et al.
Science Advances|July 19, 2024
Targeting conserved TIM3<sup>+</sup>VISTA<sup>+</sup> tumor-associated macrophages overcomes resistance to cancer immunotherapyIsaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, et al.
Nature Medicine|May 21, 2024
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinomaLisa Kinget, Stefan Naulaerts, Jannes Govaerts, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Cell Discovery|November 15, 2023
Single cell dynamics of tumor specificity vs bystander activity in CD8<sup>+</sup> T cells define the diverse immune landscapes in colorectal cancerDaniel Morales Borràs, Sara Verbandt, Markus Ausserhofer, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Molecular Oncology|January 21, 2026
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunityIsaure Vanmeerbeek, Jenny Sprooten, Abhishek D Garg
Genes and Immunity|June 3, 2021
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapyIsaure Vanmeerbeek, Daniel M Borras, Jenny Sprooten, et al.
Immunological Reviews|November 8, 2023
The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapyRaquel S Laureano, Isaure Vanmeerbeek, Jenny Sprooten, et al.
Cells|December 11, 2022
The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-OncologyIsaure Vanmeerbeek, Jannes Govaerts, Raquel S Laureano, et al.
Oncoimmunology|February 1, 2020
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncologyIsaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
Oncoimmunology|October 14, 2024
Trial watch: anticancer vaccination with dendritic cellsFrancisca Borges, Raquel S Laureano, Isaure Vanmeerbeek, et al.
Science Advances|July 19, 2024
Targeting conserved TIM3<sup>+</sup>VISTA<sup>+</sup> tumor-associated macrophages overcomes resistance to cancer immunotherapyIsaure Vanmeerbeek, Stefan Naulaerts, Jenny Sprooten, et al.
Nature Medicine|May 21, 2024
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinomaLisa Kinget, Stefan Naulaerts, Jannes Govaerts, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Cell Discovery|November 15, 2023
Single cell dynamics of tumor specificity vs bystander activity in CD8<sup>+</sup> T cells define the diverse immune landscapes in colorectal cancerDaniel Morales Borràs, Sara Verbandt, Markus Ausserhofer, et al.
Pageof 2